# Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma

> **NCT00859469** · PHASE2 · COMPLETED · sponsor: **Columbia University** · enrollment: 29 (actual)

## Conditions studied

- Mesothelioma

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00859469
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2009-03
- **Final completion:** 2013-03
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2019-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00859469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00859469, "Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00859469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*